<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Sle on Rheumatology Digest</title><link>https://rheumatologydigest.org/tags/sle/</link><description>Recent content in Sle on Rheumatology Digest</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Mon, 11 May 2026 17:30:00 +0530</lastBuildDate><atom:link href="https://rheumatologydigest.org/tags/sle/index.xml" rel="self" type="application/rss+xml"/><item><title>Cellular therapies for rheumatic disease</title><link>https://rheumatologydigest.org/posts/cellular-therapies-for-rheumatic-disease/</link><pubDate>Mon, 11 May 2026 17:30:00 +0530</pubDate><guid>https://rheumatologydigest.org/posts/cellular-therapies-for-rheumatic-disease/</guid><description>CD19 CAR-T cellular therapy delivers drug-free remission in 80–85% of refractory SLE patients in early-phase trials, with similar signals in IIM and SSc — the first credible attempt at true immunological reset in autoimmune rheumatic disease.</description></item></channel></rss>